Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome

LK Schwartz, SJD O'keefe, K Fujioka… - Clinical and …, 2016 - journals.lww.com
OBJECTIVES: In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide
significantly reduced parenteral support (PS) requirements in patients with short bowel
syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed to
evaluate long-term safety and efficacy of teduglutide. METHODS: Enrolled patients had
completed 24 weeks of either teduglutide (TED/TED) or placebo (PBO/TED) in the initial
placebo-controlled study or qualified for that study, but were not treated (NT/TED) because …